Cargando…
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities
SIMPLE SUMMARY: CAR T-cell therapy became standard of care for patients with relapsed or refractory large B-cell lymphoma. However, their administration can be accompanied by toxicities, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. It is important to...
Autores principales: | de Boer, Janneke W., Keijzer, Kylie, Pennings, Elise R. A., van Doesum, Jaap A., Spanjaart, Anne M., Jak, Margot, Mutsaers, Pim G. N. J., van Dorp, Suzanne, Vermaat, Joost S. P., van der Poel, Marjolein W. M., van Dijk, Lisanne V., Kersten, Marie José, Niezink, Anne G. H., van Meerten, Tom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670876/ https://www.ncbi.nlm.nih.gov/pubmed/38001703 http://dx.doi.org/10.3390/cancers15225443 |
Ejemplares similares
-
Inflammatory reactions mimic residual or recurrent lymphoma on [(18)F]FDG-PET/CT after CD19-directed CAR T-cell therapy
por: de Boer, Janneke W., et al.
Publicado: (2023) -
Semi-automated (18)F-FDG PET segmentation methods for tumor volume determination in Non-Hodgkin lymphoma patients: a literature review, implementation and multi-threshold evaluation
por: Keijzer, Kylie, et al.
Publicado: (2023) -
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
por: Spanjaart, Anne M., et al.
Publicado: (2023) -
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
por: Spanjaart, Anne M., et al.
Publicado: (2023) -
P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE
por: Spanjaart, A. M., et al.
Publicado: (2022)